Latex-Free Supplier Claims: What Evidence and Label Wording to Require

The scenario: four supplier answers to one tender clause

A distributor RFQ or hospital tender for sterile single-use consumables, such as puncture kits, catheter securement sets, dressings or procedure packs, often includes a line like “devices and packaging must be suitable for a latex-safe environment.” The replies often look like this illustrative set:

• Supplier A puts a banner on the quotation: “100% latex-free guaranteed.”
• Supplier B sends a catalogue sheet saying: “Does not contain natural rubber latex.”
• Supplier C sends a signed statement that natural rubber latex “is not a primary raw material in the fluid path”. At least one large supplier uses this exact wording. ¹⁹
• Supplier D is asked for a test certificate proving there is no latex. It replies that no such test exists and offers an ASTM D5712 protein report from three years ago.

Supplier D is closest to the regulatory position on testing. Supplier A is using the wording FDA most clearly advises against. Supplier C may be entirely accurate, but it answers a narrower question than the tender asked. This guide explains how to tell these answers apart and what to write into the RFQ so bidders’ answers can be compared.

Who this is for: distributors, private-label and OEM buyers, hospital procurement teams, and QA/RA staff who must accept or reject a supplier’s latex claim for US or EU supply. It does not address the clinical management of latex allergy. Questions about use with allergic patients belong with clinicians and the instructions for use.

Why does FDA discourage “latex-free”?

FDA’s December 2014 final guidance applies to devices, drugs, biologics and veterinary products. It says statements such as “latex-free,” “does not contain natural rubber latex” or “does not contain latex” are not accurate, because the absence of the allergens behind natural-rubber-latex reactions cannot be reliably assured. FDA adds that such statements may give allergic users a false sense of security. ¹ The guidance gives three reasons:

1. The word is ambiguous. “Latex” can mean natural rubber latex or a synthetic latex that is not derived from it, so the statement does not name the material of concern. ¹
2. No method can show absence. FDA says it knows of no test method, or combination of methods, that can demonstrate the absence of natural-rubber-latex proteins or components that may cause allergic reactions. ¹
3. Contamination is not addressed. “Free” and “does not contain” say nothing about accidental contamination of the product or its container during or after manufacturing. ¹

The guidance also includes context that marketing copy usually leaves out. At least 13 natural-rubber-latex allergens have been identified. Threshold allergen levels are not available for latex-allergic people, and no single exposure level can be considered safe. ¹ FDA also says complete absence of all allergens is “unlikely to be necessary” for safe use. The problem is that current methods cannot show where a safe level lies. ¹ FDA’s conclusion is that these statements are “not scientifically supportable”, and it “strongly recommends” keeping them out of medical product labeling. ¹

Two boundaries matter for buyers. First, this is guidance: FDA states that it does not establish legally enforceable responsibilities. Second, no regulation requires a “not made with” statement at all, so a supplier may legitimately say nothing. ¹ A buyer can still make accurate wording a contract requirement, which is what the RFQ block below does.

What can protein tests actually prove?

A request for a report “proving zero latex” asks for something FDA says does not exist. ¹ The test methods that do exist were written to characterize products made from Hevea natural rubber, and each one states its own limits.

What this means in practice. A protein result is useful for a product that is known to contain natural rubber, for example to show that a glove or catheter process keeps extractable protein low. For a product that should contain no natural rubber at all, a low or non-detectable result fits the claim but cannot prove it. None of these methods measures everything that can cause a reaction. ^{1 7} The primary evidence for a “not made with” claim is therefore a record of the materials used, backed by the supplier’s design and purchasing controls, not a laboratory certificate.

The contamination scope added in D6499-24 does help with one question. If the concern is cross-contact on a shared production line, a D6499-24 result shows whether antigenic Hevea protein was detected on the items tested. It answers “how much antigen did this method find on these samples”, not “is this product free of allergens”. ⁷

Which latex wording should a buyer accept?

FDA recommends “Not made with natural rubber latex.” The statement says that natural rubber latex, or synthetic derivatives of it, was not used as a material. It makes no claim that the product is free of latex contamination. ¹ If only part of the product qualifies, FDA recommends naming that part. Its example is “The <vial stopper> is not made with natural rubber latex.” ¹ The EU has no equivalent recommended sentence. It relies instead on the MDR’s ban on misleading claims, on label warnings and on symbols. ^{10 15}

Scope: what an unqualified claim covers, and what the caution rule covers

Most claim errors are scope errors. Two different rules apply, and they draw the line in different places.

• Voluntary statement. An unqualified “Not made with natural rubber latex” applies to the medical product, its container and any packaging. ¹ Natural rubber anywhere in that set, whether in a device component, a pouch seal or a carton adhesive, makes the unqualified statement inaccurate. The supplier must either name the component that qualifies or drop the claim.
• Mandatory caution. 21 CFR 801.437 applies to devices, components or packaging that contain natural rubber that “contacts humans”. That means the rubber is intended or likely to contact the user or patient. It includes connection to the patient through a liquid path or an enclosed gas path, and powder that may carry natural-rubber proteins into the user’s or patient’s environment. ² When the rule took effect, FDA said that packaging using natural rubber only on adhesives in the flaps of device packaging is not subject to it, because those adhesives are not intended or likely to contact humans. ⁴

This leaves a gap buyers should watch for. A natural-rubber adhesive on a carton flap may not trigger a caution statement, yet it still makes an unqualified “not made with” claim inaccurate. ^{1 4}

Cold-seal packaging adhesives

Cold-seal (cohesive) coatings bond to themselves under pressure, without heat. FDA addressed them directly. In 1998 it stayed the packaging caution requirements in paragraphs (f) and (g) until 27 June 1999 for device packaging that uses cold-seal adhesives, while the rest of the rule took effect as planned. ⁴ The note still appears in the codified text. ² Natural rubber remains an ingredient in some cold-seal products. One major adhesive maker says its food-packaging cold seals combine natural rubber latex with synthetic emulsions, and separately offers synthetic water-based acrylic cold seals for medical overwraps such as bandages. ²⁰ The material therefore depends on the product the converter chose, and the buyer has to ask.

The same question applies to any sealed package, whether it is cold-sealed or heat-sealed: what are the seal coating, labels and tapes made of? Identify how each package level is sealed, and obtain the coating or adhesive supplier’s material statement for each. Sterile-barrier performance is a separate topic, covered in our sterile barrier packaging and shelf-life validation guide.

Read the scope of the declaration, not its headline

Supplier statements often answer a narrower question than the tender asks. Cytiva’s latex compliance statement for listed bioprocess single-use products says natural rubber latex “is not a primary raw material in the fluid path”. Separately, it lists named manufacturing sites as latex-free manufacturing facilities. ¹⁹ That may be exactly right for a bioprocess user worried about the fluid path. It says nothing about housings, external grips or packaging, so a tender covering every handled surface and every package layer needs more. The same caution applies to supplier pages that present “latex-free” and “Not made with natural rubber latex” as interchangeable label claims. ²¹ The exact words matter because they define what the supplier is accountable for.

When natural rubber is present: 21 CFR 801.437

The “not made with” guidance is voluntary. The rule for devices that do contain natural rubber is not. 21 CFR 801.437 applies to devices “composed of or containing, or having packaging or components that are composed of, or contain, natural rubber that contacts humans.” Natural rubber here includes natural rubber latex, dry natural rubber, and synthetic latex or synthetic rubber that contains natural rubber in its formulation. ² Synthetic latex or rubber with no natural rubber in its formulation is outside the rule. ³

FDA’s compliance guide gives examples. Natural rubber latex (formed by dipping, extruding or coating) appears in items such as gloves, catheters, wound drains and condoms. Dry natural rubber (formed from coagulated sheets by molding or extrusion) appears in items such as syringe plungers, vial stoppers, intravenous injection ports, electrode pads and the elastic components of bandages. ³

Several other provisions matter in a supplier review:

• Each statement must be prominent and legible, as required by section 502(c) of the Federal Food, Drug, and Cosmetic Act. ²
• A device that contains natural rubber that contacts humans may not use the term “hypoallergenic” on its labeling. FDA’s reasoning is that the word would lead people to conclude, wrongly, that the product cannot cause latex protein reactions. ^{2 3}
• A device not labeled in line with paragraphs (d) to (h) is misbranded under sections 201(n) and 502(a), (c) and (f) of the Act. ²
• An affected person may request an exemption or variance by citizen petition under 21 CFR 10.30. ² If a supplier says a statement does not apply to its product, ask for the decision in writing rather than accepting an informal exception.
• If a device contains both natural rubber latex and dry natural rubber, FDA’s compliance guide says the natural-rubber-latex statement covers both. ³

What the US UDI database shows about latex labeling

Labelers must report to FDA’s Global Unique Device Identification Database (GUDID) whether a device is labeled as containing natural rubber latex that contacts humans, or as having packaging that does, as described in 21 CFR 801.437. ¹⁶ GUDID also has a separate yes/no field for devices whose labeling says natural rubber latex was not used in the product and container. openFDA notes that this second field applies only to devices not subject to 801.437, and that not every product made without natural rubber latex is marked. ¹⁷ Both fields are public through AccessGUDID and the openFDA device UDI endpoint. ^{17 18}

We counted both fields across the openFDA UDI dataset, which was last updated on 1 October 2026 and queried on 20 October 2026. The count is limited to the 4,738,084 records marked “In Commercial Distribution”. ¹⁷

Two patterns stand out. Kits make up 18% of the records but 65% of those labeled as containing natural rubber (49,536 of 76,366). Their rate of natural-rubber labeling is about eight times the non-kit rate. By FDA device name, the largest groups of natural-rubber-labeled records are general surgery trays (16,626 records), medical support stockings (9,493) and cardiovascular procedure kits (9,408). ¹⁷ Kits are also where “not made with” labeling is most common: 57% of kit records carry it, compared with 8% of non-kit records.

Limits. These are counts of GUDID device-identifier records, not of products, sales or units. Makers of custom procedure trays register many configurations, which inflates kit counts. The fields are submitted by labelers, and openFDA describes its data as unvalidated. A blank “not made with” field does not mean a device contains natural rubber. ¹⁷ Device-name counts can overlap when a record lists more than one product code.

For a US-marketed device, the practical use is simple. Look up the device identifier in AccessGUDID and compare its two latex fields with the supplier’s quotation and label artwork. ^{16 18} A device flagged as containing natural rubber cannot accurately be offered under an unqualified “not made with” claim. Any mismatch between artwork and GUDID is a documentation finding to resolve before award. For how UDI records are assigned for private-label and OEM devices, see our UDI guide for private-label single-use devices.

How does the EU handle latex claims under MDR?

The MDR does not prescribe a latex sentence. Latex information reaches the buyer through four provisions:

• Claims. Article 7 prohibits text or signs in labeling, instructions, making available and advertising that may mislead about a device’s safety or performance, including by attributing properties the device does not have. ¹⁰
• Label warnings. Annex I Section 23.2(m) requires the label to carry warnings or precautions that need the user’s immediate attention. More detail may go in the instructions for use. ¹⁰
• Symbols. Under Section 23.1(h), symbols must conform to harmonised standards or common specifications, or be described in the documentation supplied with the device. ¹⁰ EN ISO 15223-1:2021 is harmonised under the MDR, now together with its 2025 amendment. ¹² Its symbol 5.4.5 shows natural rubber or dry natural rubber as a material of construction in the device or its packaging, and the standard says not to use it for synthetic rubber. The standard has no dedicated “not made with” symbol. Its informative Annex B permits a negation (a large “X” over a symbol, following IEC 80416-3) where no “does not” symbol exists, but says this is not generally recommended. It also warns that the circle-and-slash prohibition symbol means “do not” and is sometimes misused to mean “does not contain”. ¹¹ Label-acceptance questions about this standard are covered in our ISO 15223-1 label acceptance guide.
• UDI data. When registering a UDI-DI, the manufacturer must declare “containing latex (y/n)” (Annex VI Part B, item 20). A change to critical warnings, for example “containing latex or DEHP”, requires a new UDI-DI (Annex VI Part C, Section 3.9(g)). ¹⁰

The Commission’s earlier guidance on natural rubber latex, MEDDEV 2.5/9 rev.1 (February 2004), is not binding and predates the MDR. It is still a useful indication of what a reviewer may expect. For devices containing NRL, it called for a prominent indication on the primary packaging and an allergy warning. It ruled out terms such as “hypoallergenic”, “low allergenicity” and “low protein”. And it advised against precautionary “may contain natural rubber latex” statements unless justified, because they would keep devices from sensitized users unnecessarily. ¹⁵

For a buyer, the EU checks are: the latex value submitted with the UDI-DI; the presence symbol or warning where natural rubber is present; and a defined meaning for any negated symbol. A CE-marked label is not expected to carry FDA’s English sentence, and an FDA-style sentence on an EU label does not replace the UDI data element.

What evidence should the buyer request?

No test can settle the question, so the evidence is documentary and specific to one SKU and its packaging configuration. The checklist below turns the rules above into supplier-review steps.

Five ways a latex claim breaks down

These are illustrative scenarios built from the rules above, not reports of specific incidents.

1. The problem is the pouch, not the product. A dressing’s components are all synthetic and the catalogue says “latex-free”, but the overwrap uses a natural-rubber cold seal. The catalogue wording was never FDA’s recommended statement. An unqualified “not made with” statement would also be inaccurate, because it covers the packaging. ^{1 20} Fix: get packaging-level material statements before award.
2. A protein report offered as proof. A factory answers a latex question with a D5712 report showing low extractable protein. The report shows a low total-protein result on the samples tested. It does not show the product was made without natural rubber, and D5712 does not specifically measure allergenic proteins. ^{1 5} Fix: ask for the bill of materials first and treat the report as supporting data.
3. An overlooked dry-rubber part. A single-use set includes a molded stopper or valve seal of dry natural rubber in the liquid path to the patient. Because the rubber connects to the patient through a liquid path, it “contacts humans”. The device therefore needs “This Product Contains Dry Natural Rubber.” on every required label. ^{2 3} Fix: list every molded elastomer part, not only the dipped ones.
4. A kit with one rubber component. A procedure kit’s outer carton says “Not made with natural rubber latex”, but the kit includes a natural-rubber-latex tourniquet. The unqualified claim covers the whole presentation, so it is inaccurate. At most, the kit can carry component-specific wording for the parts that qualify, and it needs the 801.437(d) caution for the latex component. ^{1 2} The GUDID data above show why kits deserve this scrutiny. ¹⁷ Kit-level regulatory questions are covered in our sterile procedure kit regulation guide.
5. A fluid-path declaration used for a wider tender. A distributor relies on a statement that natural rubber latex is not a primary raw material in the fluid path. It then bids into a tender requiring every handled surface and package layer to suit a latex-safe environment. The declaration may be accurate, but it answers a different question. ¹⁹ Fix: map each tender requirement to a specific sentence in the supplier’s declaration.

RFQ specification block

Adapt this model language with your regulatory and legal advisers. Values in brackets are the buyer’s choice.

RFQ CLAUSE: NATURAL RUBBER LATEX STATUS

1. Declaration. For each SKU, the Supplier shall state whether natural rubber latex, dry natural rubber, or synthetic rubber containing natural rubber is used in (a) the device and each component, (b) each package level and its sealing materials, and (c) any kit component. The Supplier shall provide a signed component-level material list supporting the statement.

2. Wording. Labels, instructions for use and quotation documents shall not use “latex-free”, “does not contain latex” or “does not contain natural rubber latex”. Where natural rubber latex was not used in the product, its container or any packaging, the Supplier may state “Not made with natural rubber latex”. Where this is true of a component only, the statement shall name the component.

3. Presence. Where natural rubber that contacts humans is present, labeling shall carry the applicable 21 CFR 801.437 statement for US supply and the required warning for EU supply, using EN ISO 15223-1 symbol 5.4.5 where symbols are used. Labeling shall not use the term “hypoallergenic”.

4. Symbols. Any negated or crossed-out latex symbol shall be identified and explained in the instructions for use or symbols glossary.

5. Database consistency. The Supplier shall provide the GUDID and/or EUDAMED latex values for each device identifier and confirm that they match the labeling.

6. Change notification. The Supplier shall give at least [90] days’ written notice before changing any elastomer compound, adhesive or coating, packaging material, or supplier of these, where the change could affect latex status.

Where VEMERIX fits—and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care.

Latex questions apply to the sterile single-use lines in that portfolio. Examples are the ultrasound guidance puncture kit, with its probe sleeves and needle guide, and the disposable catheter fixer set, which has an adhesive skin-contact base. Our public product pages do not state natural-rubber-latex status. Treat the latex status of any VEMERIX SKU the way this guide recommends for every supplier: as a documentation request for the specific SKU, packaging configuration and destination market, not an assumption.

Due diligence starts with the declaration in the RFQ block above, the current label artwork, and the registration documents for your market. Review our quality information, then contact the VEMERIX team to request SKU-level material and packaging documentation or evaluation samples.

Frequently asked questions

Can a supplier print “latex-free” on a device sold in the US?

No regulation names the phrase, and FDA’s guidance is nonbinding. But FDA calls the phrase not scientifically supportable, strongly recommends against it, and asks manufacturers to update labeling that uses it. ¹ If the device or its packaging does contain natural rubber that contacts humans, the mandatory 801.437 statements apply whatever the marketing says. ² For procurement, do not accept “latex-free” as the contractual claim.

What is the difference between natural rubber latex and synthetic latex?

Natural latex comes mainly from the Hevea brasiliensis tree and contains plant proteins, which FDA describes as the believed primary allergen. ³ Synthetic latex or rubber with no natural rubber in its formulation is outside 21 CFR 801.437. ³ “Synthetic” is not automatically enough, though: the rule covers synthetic latex or rubber that contains natural rubber in its formulation. ²

Why does FDA recommend “Not made with natural rubber latex” instead of “latex-free”?

The recommended statement says natural rubber latex was not used as a material, which a manufacturer can document. It does not claim the product is free of latex or of contamination, which no test can show. FDA adds that consistent wording reduces confusion for its staff, manufacturers and users. ¹

Does an unqualified “Not made with natural rubber latex” claim include packaging?

Yes. FDA says an unqualified statement applies to the product, its container and any packaging. ¹ The mandatory caution rule is narrower: it covers packaging only where the natural rubber contacts humans, and FDA has said that rubber used only on packaging-flap adhesives does not. ^{2 4}

What happens if a device containing natural rubber lacks the 21 CFR 801.437 statement?

Under 801.437(j), a device subject to the section that is not labeled in line with paragraphs (d) to (h) is misbranded under sections 201(n) and 502(a), (c) and (f) of the FD&C Act. ² In GUDID, the labeler should also have reported the natural-rubber labeling for that device identifier. ¹⁶

Can an ASTM D5712 protein report show a consumable is safe for latex-allergic patients?

No. D5712 measures total aqueous extractable protein, not antigenic or allergenic protein specifically, and FDA knows of no method that can demonstrate the absence of natural-rubber-latex allergens. ^{1 5} Questions about use with allergic patients should go to clinicians and the instructions for use.

How is latex status shown for medical devices in the EU?

Through label warnings, ISO 15223-1 symbol 5.4.5 where natural rubber is present, and the “containing latex (y/n)” element submitted with the UDI-DI. ^{10 11} The MDR defines no “latex-free” wording. A negated symbol is an informative-annex option and should be explained in the documentation. ¹¹

Can GUDID confirm that a device is not made with natural rubber latex?

Only partly. The natural-rubber field reflects the 801.437 labeling the labeler reported. The “not made with” field is not filled in for every qualifying device, so a blank proves nothing either way. ^{16 17} Use GUDID as a consistency check against the supplier’s declaration and artwork, not as a substitute for them.